HC Wainwright Has Negative Outlook for VTYX FY2024 Earnings

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Ventyx Biosciences in a research note issued on Tuesday, October 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($2.14) per share for the year, down from their prior estimate of ($2.13). HC Wainwright has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q4 2024 earnings at ($0.59) EPS and FY2025 earnings at ($2.93) EPS.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12.

Several other research firms also recently weighed in on VTYX. Canaccord Genuity Group cut their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Wells Fargo & Company cut their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Ventyx Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $8.29.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX opened at $2.45 on Thursday. The company has a market capitalization of $173.14 million, a PE ratio of -0.88 and a beta of 0.36. The business has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $3.12. Ventyx Biosciences has a 1 year low of $1.79 and a 1 year high of $17.83.

Institutional Trading of Ventyx Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Norden Group LLC purchased a new stake in shares of Ventyx Biosciences in the 1st quarter valued at about $59,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ventyx Biosciences in the 1st quarter valued at about $72,000. SG Americas Securities LLC purchased a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at about $32,000. The Manufacturers Life Insurance Company raised its holdings in shares of Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at about $58,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.